C-6VCITelomir Pharmaceuticals
epigenetics, metabolism, small molecules
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-6VCI
C-6VCIC-6VCIepigenetics, metabolism, small molecules
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Telomir Pharmaceuticals epigenetics, metabolism, small molecules
Telomir Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class small-molecule therapeutics. The company targets epigenetic and metabolic pathways implicated in cancer and age-related disease. Its lead investigational candidate, Telomir-Zn, is designed to restore epigenetic regulation associated with tumor progression, genomic instability, and treatment resistance.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Telomir Pharmaceuticals — Translational · Bottom quartile. Derived deterministically from 2 extracted project(s). Most-advanced status: phase 1. Band: translational. Modifiers: +5 modality breadth (3 modalities…
Source: Deterministic